Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 01/23/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, 2017. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode will be 44112876.
A replay will be available through February 13, 2017 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode will be 44112876.
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first-generation cortisol modulator, is the company''s first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.01.2017 - 15:05 Uhr
Sprache: Deutsch
News-ID 1482027
Anzahl Zeichen: 3075
contact information:
Contact person:
Town:
MENLO PARK, CA
Phone:
Kategorie:
Drugs
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 431 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corcept Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
